Akos Czibere - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Signature
/s/ Akos Czibere
Issuer symbol
AKTS
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
3
Filing time
08 Jan 2026, 21:02:23 UTC

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Czibere Akos Chief Medical Officer C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Akos Czibere 08 Jan 2026 0002049427

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 271,218 $4.95 Direct F1
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 98,570 $9.33 Direct F2
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 19,714 $11.46 Direct F3
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 131,426 $18.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F2 25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F3 25% of the original number of shares subject to the option shall vest on November 1, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F4 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney